![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/274f680fee69fec24effec10a3cf522b1f12a7df-800x571.jpg?fit=crop&auto=format)
HER2 Gene Test Predicts Long-Term Pertuzumab Combo PFS/OS in Breast Cancer
The use of HER2DX®, a diagnostic test for HER2-positive breast cancer, showed an ability to predict long-term survival outcomes in patients with HER2-positive breast cancer who received treatment with taxane plus trastuzumab (Herceptin) and pertuzumab ( …